Drugmakers Eli Lilly and Boehringer Ingelheim said Friday that European Union regulators approved their type 2 diabetes drug Jardiance.

Jardiance was approved in two doses. The drug, also called empagliflozin, is a tablet intended to be taken once a day. It is for patients who are trying to control their blood sugar with diet and exercise but who need additional help. The drug is designed to reduce a patient's blood sugar levels by blocking glucose reabsorption in the kidneys and removing excess glucose through urine. Unlike other diabetes treatments, it does not depend on a patient's insulin levels to be effective.

Empagliflozin has not been approved in the U.S. The Food and Drug Administration didn't approve the drug in March, and Lilly and Boehringer Ingelheim said the agency was concerned about a facility where the drug will be made.

Discover a top stock pick for 2014
Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.